Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MSLN positive
i
Other names:
MSLN, CAK1, MPF, Mesothelin
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
10232
Related biomarkers:
Expression
Others
‹
›
Associations
(5)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCI-2018-01503) (NCT03587311)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/17/2024
Initiation :
10/12/2018
Primary completion :
10/21/2024
Completion :
10/21/2024
MSLN
|
MSLN positive
|
Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (NCI10208) (NCT03816358)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/16/2024
Initiation :
12/09/2019
Primary completion :
01/31/2025
Completion :
01/31/2025
MSLN
|
MSLN expression • MSLN positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours (NCT05804526)
Phase 1/2
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Recruiting
Phase 1/2
RemeGen Co., Ltd.
Recruiting
Last update posted :
04/30/2024
Initiation :
07/19/2023
Primary completion :
05/01/2025
Completion :
12/01/2025
MSLN
|
MSLN positive
|
Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852)
Phase 1/2
TCR2 Therapeutics
TCR2 Therapeutics
Active, not recruiting
Phase 1/2
TCR2 Therapeutics
Active, not recruiting
Last update posted :
03/06/2024
Initiation :
04/15/2019
Primary completion :
11/02/2028
Completion :
11/02/2028
MSLN
|
MSLN expression • MSLN positive
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849)
Phase 1/2
TCR2 Therapeutics
TCR2 Therapeutics
Active, not recruiting
Phase 1/2
TCR2 Therapeutics
Active, not recruiting
Last update posted :
03/06/2024
Initiation :
06/21/2022
Primary completion :
10/30/2028
Completion :
10/30/2028
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • TC-510
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (NCT05375825)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not yet recruiting
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
02/01/2024
Initiation :
02/06/2024
Primary completion :
12/18/2024
Completion :
12/18/2024
MSLN
|
MSLN expression • MSLN positive
|
LMB-100
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers (NCT05779917)
Phase 1
Second Affiliated Hospital of Guangzhou Medical University
Second Affiliated Hospital of Guangzhou...
Recruiting
Phase 1
Second Affiliated Hospital of Guangzhou Medical...
Recruiting
Last update posted :
11/15/2023
Initiation :
03/10/2023
Primary completion :
03/10/2026
Completion :
03/10/2033
MSLN
|
MSLN expression • MSLN positive
|
Mesothelin/GPC3/GUCY2C-CAR-T
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) (NCT01393483)
Phase N/A
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase N/A
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
10/03/2023
Initiation :
03/01/2011
Primary completion :
09/01/2024
Completion :
09/01/2024
MSLN
|
MSLN expression • MSLN positive
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (NCT04727554)
Phase 1
Amgen
Amgen
Completed
Phase 1
Amgen
Completed
Last update posted :
09/22/2023
Initiation :
04/29/2021
Primary completion :
06/05/2023
Completion :
06/05/2023
MSLN
|
MSLN expression • MSLN positive
|
inezetamab (AMG994) • zeluvalimab (AMG 404)
Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer (NCT05686720)
Phase 1
First Affiliated Hospital of Shantou University Medical College
First Affiliated Hospital of Shantou Un...
Not yet recruiting
Phase 1
First Affiliated Hospital of Shantou University...
Not yet recruiting
Last update posted :
01/16/2023
Initiation :
02/01/2023
Primary completion :
02/01/2024
Completion :
06/01/2024
HER-2 • ER • PGR • MSLN
|
HER-2 negative • ER negative • MSLN positive • PGR negative
|
SZ011
Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05141253)
Phase 1
Tongji Hospital
Tongji Hospital
Recruiting
Phase 1
Tongji Hospital
Recruiting
Last update posted :
04/27/2022
Initiation :
01/12/2022
Primary completion :
11/01/2023
Completion :
11/01/2036
MSLN
|
MSLN positive
|
RD133
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors (NCT05344976)
Phase 1
Peking University
Peking University
Not yet recruiting
Phase 1
Peking University
Not yet recruiting
Last update posted :
04/25/2022
Initiation :
04/14/2022
Primary completion :
10/14/2024
Completion :
02/01/2026
EGFR • ALK • MET • ROS1 • MSLN
|
ALK positive • EGFR positive • EGFR negative • MSLN positive
|
YTS105
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors (NCT05166070)
Phase 1
The First Affiliated Hospital with Nanjing Medical University
The First Affiliated Hospital with Nanj...
Recruiting
Phase 1
The First Affiliated Hospital with Nanjing Medi...
Recruiting
Last update posted :
12/21/2021
Initiation :
01/01/2022
Primary completion :
01/01/2024
Completion :
01/01/2037
MSLN
|
MSLN positive
|
RD133
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto) (NCT04981691)
Phase 1
Ruijin Hospital
Ruijin Hospital
Recruiting
Phase 1
Ruijin Hospital
Recruiting
Last update posted :
09/17/2021
Initiation :
10/01/2021
Primary completion :
01/09/2022
Completion :
07/09/2022
MSLN
|
MSLN positive
|
cyclophosphamide • MSLN CAR-T • UCLM802
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (NCT03814447)
Phase 1
Shanghai 6th People's Hospital
Shanghai 6th People's Hospital
Recruiting
Phase 1
Shanghai 6th People's Hospital
Recruiting
Last update posted :
08/10/2021
Initiation :
08/16/2019
Primary completion :
01/01/2023
Completion :
01/01/2023
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies (NCT03941626)
Phase 1/2
Shenzhen BinDeBio Ltd.
Shenzhen BinDeBio Ltd.
Recruiting
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
02/04/2021
Initiation :
09/01/2019
Primary completion :
05/01/2021
Completion :
12/01/2021
HLA-A • MSLN • CTAG1B
|
HLA-A*02:01 • MSLN positive • HLA-A positive
|
cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer (NCT04627740)
Phase 1/2
Xinqiao Hospital of Chongqing
Xinqiao Hospital of Chongqing
Not yet recruiting
Phase 1/2
Xinqiao Hospital of Chongqing
Not yet recruiting
Last update posted :
11/13/2020
Initiation :
12/01/2020
Primary completion :
12/31/2022
Completion :
12/31/2023
MSLN
|
MSLN positive
|
cyclophosphamide • TC-A101
Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. (NCT03545815)
Phase 1
Chinese PLA General Hospital
Chinese PLA General Hospital
Unknown status
Phase 1
Chinese PLA General Hospital
Unknown status
Last update posted :
08/10/2020
Initiation :
03/19/2018
Primary completion :
10/30/2020
Completion :
12/30/2020
MSLN
|
MSLN positive
|
GC008t • MPTK-CAR-T cells • MSLN CAR-T
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer (NCT03916679)
Phase 1/2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Second Affiliated Hospital, School of M...
Recruiting
Phase 1/2
Second Affiliated Hospital, School of Medicine,...
Recruiting
Last update posted :
04/16/2019
Initiation :
04/20/2019
Primary completion :
04/20/2022
Completion :
04/20/2023
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (NCT03799913)
Phase 1
Zhejiang University
Zhejiang University
Unknown status
Phase 1
Zhejiang University
Unknown status
Last update posted :
04/10/2019
Initiation :
04/10/2019
Primary completion :
10/01/2021
Completion :
04/01/2022
MSLN
|
MSLN expression • MSLN positive
|
cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells
Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer (NCT03692637)
Phase 1
Allife Medical Science and Technology Co., Ltd.
Allife Medical Science and Technology C...
Unknown status
Phase 1
Allife Medical Science and Technology Co., Ltd.
Unknown status
Last update posted :
01/31/2019
Initiation :
03/01/2019
Primary completion :
11/01/2020
Completion :
11/01/2021
PD-L1 • PD-1 • MSLN
|
MSLN expression • MSLN positive
|
MSLN CAR-T • anti-Mesothelin CAR NK Cells
Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors (NCT03747965)
Phase 1
Chinese PLA General Hospital
Chinese PLA General Hospital
Unknown status
Phase 1
Chinese PLA General Hospital
Unknown status
Last update posted :
11/20/2018
Initiation :
11/01/2018
Primary completion :
11/01/2019
Completion :
05/01/2020
MSLN
|
MSLN positive
|
paclitaxel • cyclophosphamide • GC008t
PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies (NCT03030001)
Phase 1/2
Ningbo Cancer Hospital
Ningbo Cancer Hospital
Unknown status
Phase 1/2
Ningbo Cancer Hospital
Unknown status
Last update posted :
01/24/2017
Initiation :
02/15/2017
Primary completion :
12/01/2018
Completion :
02/01/2019
MSLN
|
MSLN positive
Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors (NCT02930993)
Phase 1
China Meitan General Hospital
China Meitan General Hospital
Unknown status
Phase 1
China Meitan General Hospital
Unknown status
Last update posted :
10/12/2016
Initiation :
08/01/2016
Primary completion :
08/01/2018
Completion :
08/01/2019
MSLN
|
MSLN positive
|
cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells
A Study of MORAb-009 in Patients With Solid Tumor (MORAB-009-J081-102) (NCT01018784)
Phase 1
Eisai Co., Ltd.
Eisai Co., Ltd.
Completed
Phase 1
Eisai Co., Ltd.
Completed
Last update posted :
01/21/2016
Initiation :
11/01/2009
Primary completion :
05/01/2012
Completion :
02/01/2013
MSLN
|
MSLN positive
|
amatuximab (MORAb-009)
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso (NCT02580747)
Phase 1
Chinese PLA General Hospital
Chinese PLA General Hospital
Unknown status
Phase 1
Chinese PLA General Hospital
Unknown status
Last update posted :
10/20/2015
Initiation :
10/01/2015
Primary completion :
11/01/2017
Completion :
11/01/2018
MSLN
|
MSLN positive
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login